Abstract: Postimplant calcific degeneration is a frequent cause of clinical failure of glutaraldehyde crosslinked porcine aortic valve bioprostheses. We demonstrated previously in rat subdermal and circulatory implants that a-amino oleic acid used as a bioprosthesis pretreatment was highly effective in mitigating aortic valve cusp but not aortic wall calcification. In this study we investigated the feasibility of synergistically applying two proven anticalcification agents (a-amino oleic acid and FeCl 3 ) as pretreatments for mitigating both bioprosthetic cusp and aortic wall calcification. a-Amino oleic acid is hypothesized to prevent calcification by disrupting calcium phosphate formation kinetics, whereas suppression of alkaline phosphatase activity and ferric-phosphate complexation at cellular membrane initiation sites may be important factors in ferric ion's inhibition of calcification. In vivo implant studies (21-day rat subdermal model) indicated that individually FeCl 3 (0.01 or 0.1 M for 24 h) or a-amino oleic acid (saturated solution) treatments were equally effective in mitigating cuspal calcification (tissue calcium levels: 30.2 { 10.2, 29.8 { 2.7, and 31.6 { 7.8 mg/mg tissue, respectively). However, sequential application of first a-amino oleic acid and then FeCl 3 synergistically reduced aortic wall calcification more effectively than either of the agents alone. The benefit of a synergistic application of two anticalcification treatments, a-amino oleic acid and FeCl 3 , was demonstrated. However, the synergistic effect was observed on aortic wall only at a higher FeCl 3 concentration (i.e., 0.1 M).
INTRODUCTION
than mature subjects. 3 Therefore, immature animals are used in all experimental studies. Mechanical factors are of importance, because observations of circulatory implants Calcific degeneration impairs the long-term clinical perforindicate enhanced calcification at sites of greatest stress/ mance of bioprosthetic heart valves (BPHVs) fabricated strain phenomena. 3 Initial calcification occurs at the devifrom porcine aortic valves crosslinked with glutaraldehyde. 1 It was previously postulated that bioprosthetic calcitalized cell membranes, intrinsic to the glutaraldehyde fication is a multifactorial process. 2 BPHV calcification crosslinked bioprosthetic tissue. 3, 4 Following this, collagen occurs as an interaction of host, implant, and mechanical calcification in aortic cusp and elastin calcification in aortic factors. Glutaraldehyde crosslinking is the most important wall become progressively involved. 3, 4 To date, anticalciimplant factor-without this preparation step, subdermal fication strategies have focused on prevention rather than implants of xenograft valve cusp materials do not calcify. 3 therapeutic measures to arrest or cause regression of ongoThe most important host factor is young age, with immature ing calcification. Although various strategies for countersubjects calcifying bioprosthetic implants more severely acting this mineralization process have been investigated experimentally, no completely satisfactory method is currently available clinically for complete inhibition of BPHV calcification. for inhibiting calcification of glutaraldehyde pretreated bovine pericardium in rat subdermal implants 13 and in a separate study to inhibit aortic wall calcification of glutaraldehyde pretreated rat aortic allograft circulatory implants. Alkaline phosphatase inhibition by FeCl 3 was also demonRat subdermal implants 17,18 were used to assess the anticalcification efficacy of a-amino oleic acid, a-amino oleic strated to play a role in the anticalcification mechanism.
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The objective of the present study was to investigate acid/FeCl 3 , and FeCl 3 on both cusp and aortic wall. Tissues were implanted into male weaning rats (3-week-old, 50-the possibility of a synergistic use of a-amino oleic acid and FeCl 3 pretreatments for inhibiting calcification of both 60 g, Sprague-Dawley; Charles River Laboratories, Burlington, MA), anesthetized with a mixture of ketamine bioprosthetic cusp and aortic wall.
(100 mg/mL) and xylazine (20 mg/mL), in subdermal pouches dissected in the ventral abdominal wall as described previously. 18 Each animal received two separate MATERIALS AND METHODS subdermal implants. After 21 days, the rats were euthanized by carbon dioxide inhalation and the tissue specimens were Materials retrieved. All tissue specimens were rinsed with deionized Fresh and glutaraldehyde crosslinked porcine aortic valve water and lyophilized. Representative samples fixed with tissues (both cusp and aortic wall prepared according to a combined glutaraldehyde-formaldehyde fixative 19 soluproprietary procedures approved for clinical use) were dition were processed for light microscopy using glycomethrectly supplied by the Heart Valve Division of Medtronic acrylate embedding medium and staining with hematoxylin Inc. (Irvine, CA). FeCl 3 was obtained from Aldrich Chemiand eosin (for overall morphology) and von Kossa's recal Inc. (Milwaukee, WI). All other chemicals were reagent (for calcium phosphate) according to previously deagent grade; distilled and deionized water was used.
scribed methods. 20 Acid hydrolysates of specimens were a-Amino oleic acid was synthesized at Medtronic Inc. subjected to calcium analysis by atomic absorption spec-(Minneapolis, MN) and the a-amino oleic acid solution troscopy using previously described procedures. 18, 20 was provided to our laboratory as a saturated solution prepared under proprietary conditions also utilized to prepare
Data and Statistical Analyses
clinically implantable heart valve bioprostheses.
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Replicate data were calculated and expressed as mean { standard error of the mean (SEM). Unpaired t tests were
Treatment of Tissues (Cusp and Aortic Wall) with
used to assess the significance of statistical differences be-
a-Amino Oleic Acid and FeCl 3
tween experimental groups and controls. Results were termed significant when the p value was less than 0.05. Glutaraldehyde fixed cusps were treated with a saturated a-amino oleic acid solution (approximately 1 mL a-amino oleic acid solution for 20 mg of wet tissue) for 72 h (at 37ЊC). Groups of a-amino oleic acid treated cusp tissues RESULTS were subsequently incubated for 24 h with either 0.01 or 0.1 M FeCl 3 solutions at 37ЊC. Similarly, aortic wall sam-
The extent of inhibition of calcification on a-amino oleic acid/FeCl 3 treated cusp and aortic wall with respect to the ples were pretreated with the a-amino oleic acid solution and the FeCl 3 solutions in sequence. Two additional groups concentration of FeCl 3 for tissue treatment, after 3 weeks of implantation, is illustrated in Tables I and II . Sequential of tissues (not exposed to a-amino oleic acid) were similarly treated with 0.01 or 0. (Fig. 1) . The results of the rat subdermal implant study indicated Some experimental strategies have been proven effective that FeCl 3 (at concentrations of 0.01 and 0.1 M) had an for mitigating calcification of cusps. 3, 8, 21 However, many anticalcification effect on cusps (see Table I ) and was at of the strategies devised for preventing cuspal calcification least as effective as that of a-amino oleic acid when applied have failed to effectively inhibit aortic wall calcification, (Table  enhanced the anticalcification effectiveness of either agent II). However, the difference was statistically insignificant applied alone to the aortic wall. (p ú 0.2). The sequential application of first a-amino oleic As described above, a-amino oleic acid is in part covaacid and then FeCl 3 (0.01 M) significantly reduced the lently bound to BPHV tissue, both cusp and aortic wall, calcification of aortic wall as compared to control (p Å presumably through an amino-aldehyde reaction. The 0.00006). The 0.1 M FeCl 3 was also very effective in remechanism of a-amino oleic acid inhibition of calcification ducing aortic wall calcification, whereas a-amino oleic acid is incompletely understood. Detergent pretreatments of alone was significantly less effective (p ú 0.05). NevertheBPHVs have been shown in a number of studies to inhibit less, the sequential application of both a-amino oleic acid calcification. 21 The mechanism of this effect is presumably and FeCl 3 (0.1 M) significantly decreased aortic wall calcidue to surfactant extraction of phospholipids and other fication to approximately one-third of the level noted with components mediating the calcification mechanism. leaflets. Thus, calcium phosphate formation kinetics may the growth of calcium phosphate crystals on the elastin of aortic wall, thereby reducing calcification. 25, 26 be significantly altered by this phenomenon, and this may explain the efficacy of a-amino oleic acid. a-Amino oleic acid and FeCl 3 synergism could occur due to the distinct separate actions of each of these agents, However, the mechanism of FeCl 3 inhibition of calcification would at least appear to be distinct from that of thereby combining to achieve a relatively greater inhibition of calcification. However, in our studies the synergy was a-amino oleic acid. FeCl 3 pretreatment of glutaraldehyde crosslinked bovine pericardium, and in separate studies of only apparent for aortic wall calcification. Therefore, this potent combination of a-amino oleic acid and FeCl 3 may aortic wall, was demonstrated to result in the inhibition of calcification of these tissues in subdermal implants (peribe most useful for the unique elastin oriented calcification characteristic of aortic wall mineral deposition. Although cardium) and circulatory aortic allografts in rats.
14 FeCl 3 inhibition of bioprosthetic calcification is incompletely unaortic wall calcification is not clinically significant in stented BPHV implants, it is potentially of importance in derstood. Evidence from previous studies suggests that ferric-phosphate complexation at cellular membrane initiathe mineralization of stentless valves because aortic wall calcific deposits could become large enough to mechanition sites may be an important factor in the ferric ion mechanism of inhibition of calcification. In addition, FeCl 3 cally impinge on the lumen of the aortic wall segment that is normally part of a stentless valve conduit implant. This pretreatment of pericardial bioprosthetic subdermal implants inhibits the alkaline phosphatase activity usually asphenomenon has not been observed as yet in the clinical use of stentless valves. However, aortic wall calcification sociated with the initiation and progression of calcification. 11 Studies of calcium phosphate crystallization indicate has been reported to be a major cause of obstruction of aortic valve allografts in several clinical studies. 21 Thus, that ferric chloride is a potent inhibitor of calcium phosphate crystal growth. 23 Furthermore, ferric salts exposure a-amino oleic acid-FeCl 3 synergy may be of relevance in avoiding this problem for the use of stentless valves. It was implicated in renal osteodystrophy, suggesting another avenue for interaction and interference with calcium phosshould also be noted that previous work from our laboratory demonstrated that 21-day rat subdermal bioprosthetic phate formation. 24 It was proposed by Urry and Long that the calcium ion has high affinity toward elastin (a major leaflet implants result in calcium levels identical to those noted in failed clinical BPHVs. Although these same data component of aortic wall). 25, 26 The coordination of calcium ion with elastin raises the hypothetical possibility that the are not as widely available for the aortic wall, a recent publication from our group indicates a similar result, that attraction of phosphate ions to complexed calcium eventually results in elastin calcification. Ferric ion could inhibit is, the level of aortic wall calcium in our 21-day subdermal 519b / 8H09$$519B 09-10-97 09:29:31 jbmal W-JBM
